

Non GAAP reconciliation for segment operating profit

	2008 Twelve Months			2007 Twelve Months		
	As Reported	Adjs.	Adj. Op Prof	As Reported	Adjs.	Adj. Op Prof
<b>Operating Profit</b>						
<b>Consumer</b> <sup>(1)</sup>	\$ 2,674	57	<b>2,731</b>	\$ 2,277	15	<b>2,292</b>
<b>Pharmaceutical</b> <sup>(2)</sup>	7,605	-	<b>7,605</b>	6,540	1,107	<b>7,647</b>
<b>Med Devices &amp; Diagnostics</b> <sup>(3)</sup>	7,223	(255)	<b>6,968</b>	4,846	1,108	<b>5,954</b>
<b>Total segments</b> <sup>(4)</sup>	17,502	(198)	<b>17,304</b>	13,663	2,230	<b>15,893</b>

	2008 Twelve Months			2007 Twelve Months		
	As Reported	Adjs.	Adj. Op Margin	As Reported	Adjs.	Adj. Op Margin
<b>Operating Margin</b>						
<b>Consumer</b> <sup>(1)</sup>	16.7%	0.3%	<b>17.0%</b>	15.7%	0.1%	<b>15.8%</b>
<b>Pharmaceutical</b> <sup>(2)</sup>	31.0%	-	<b>31.0%</b>	26.3%	4.5%	<b>30.8%</b>
<b>Med Devices &amp; Diagnostics</b> <sup>(3)</sup>	31.2%	-1.1%	<b>30.1%</b>	22.3%	5.1%	<b>27.4%</b>
<b>Total segments</b> <sup>(4)</sup>	27.4%	-0.3%	<b>27.1%</b>	22.4%	3.6%	<b>26.0%</b>

(1) 4Q litigation charge of \$50 million and IPR&D related to Health Media of \$7 million in 2008  
Restructuring expense of \$15 million in 2007

(2) NATRECOR<sup>(R)</sup> intangible asset write-down of \$678 million and restructuring expense of \$429 million in 2007

(3) Net 4Q litigation gain of \$429 million and IPR&D of \$174 million related to SurgRx, Amic, and Omrix in 2008  
Restructuring expense of \$301 million in 2007 and IPR&D of \$807 million related to the acquisition of Conor Medsystems in 2007

(4) Net 4Q litigation gain of \$379 million and IPR&D of \$181 million related to the acquisition of Health Media, SurgRx, Amic, and Omrix in 2008  
NATRECOR<sup>(R)</sup> intangible asset write-down of \$678 million, restructuring expense of \$745 million in 2007; and IPR&D of \$807 million related to the acquisition of Conor Medsystems in 2007